Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resmetirom. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 19/20 | 0.88 |
| ▸ | THRA | P10827 | 19/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.88 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.88 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resmetirom SCHEMBL22551617 | 0.97 | THRA (0.90) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL27166008 | 0.94 | THRA (0.78) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23245123 | 0.94 | THRA (0.78) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL30046150 | 0.94 | THRA (0.78) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL30864240 | 0.94 | THRA (0.78) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL2927241 | 0.94 | THRA (1.00) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL23828935 | 0.93 | THRA (0.76) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL23245105 | 0.93 | THRA (0.76) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL23828954 | 0.92 | THRA (0.80) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL22632647 | 0.89 | THRA (0.91) | THRATHRBCYP2C9CYP2C8UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725779-B1 | SUBSTITUTED PYRIDAZINONE COMPOUND | SHENZHEN TARGETRX CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-12358899-B2 | Thyroid hormone receptor agonists and uses thereof | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| EP-4574208-A2 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-06-25 | — | — | EP | disclosed |
| EP-3807267-B1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20240360106-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2024-10-31 | — | — | US | disclosed |
| US-11964964-B2 | Thyroid hormone receptor agonists and uses thereof | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-04-23 | — | — | US | disclosed |
| US-11485729-B2 | Substituted pyridazinone compound | SHENZHEN TARGETRX, INC. (CN) | 2022-11-01 | — | — | US | disclosed |
| US-20210292304-A1 | DEUTERATED MGL-3196 COMPOUND AND USE THEREOF | HINOVA PHARMACEUTICALS INC. (CN) | 2021-09-23 | — | — | US | disclosed |
| US-20210115022-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| CN-110627773-B | Deuterated MGL-3196 compound and application thereof | 海创药业股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200347035-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND | SHENZHEN TARGETRX, INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3725779-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND | Shenzhen TargetRx, Inc. (CN) | 2020-10-21 | — | — | EP | disclosed |
| CN-111592528-A | Deuterated pyridazinone, derivatives thereof and pharmaceutical compositions | 苏州泽璟生物制药股份有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-110627773-A | Deuterated MGL-3196 compound and application thereof | 成都海创药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964964-B2 | Thyroid hormone receptor agonists and uses thereof | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885CYP2C9 2934/4885 |
| US-20210115022-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885CYP2C9 2934/4885 |
| US-20240360106-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885CYP2C9 2934/4885 |
| US-12358899-B2 | Thyroid hormone receptor agonists and uses thereof | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885CYP2C9 2934/4885 |
| US-11485729-B2 | Substituted pyridazinone compound | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885CYP2C9 845/4885 |
| US-20210292304-A1 | DEUTERATED MGL-3196 COMPOUND AND USE THEREOF | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885CYP2C9 633/4885 |
| US-20200347035-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885CYP2C9 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.